Incretin Drugs Cause Alarming Muscle Loss

Popular incretin-based medications, including semaglutide and tirzepatide, are increasingly linked to unexpected levels of muscle loss during weight reduction, according to a study published in the Annals of Internal Medicine. Researchers analyzed multiple studies and found that muscle tissue comprised approximately 35% of the total weight lost in patients using these therapies, surpassing safe benchmarks in two-thirds of instances.

While these drugs effectively aid in weight reduction for individuals with type 2 diabetes and obesity by suppressing appetite, the concurrent loss of lean muscle mass is a growing concern. This proportion of muscle loss is significantly higher than that typically observed with non-drug weight loss methods like dieting alone.

The implications are particularly serious for older adults, a demographic often underrepresented in clinical trials. For individuals over 60, increased muscle loss can lead to greater frailty, a higher risk of falls, and reduced mobility, significantly impacting their quality of life and independence.

Preventative measures focus on a multi-faceted approach. Incorporating resistance training at least twice weekly is crucial for stimulating muscle repair and growth. Complementing this with a high-protein diet, aiming for 1.2-1.6 grams per kilogram of body weight daily, supports muscle protein synthesis. Maintaining daily activity through aerobic and balance exercises further aids in preserving muscle function and preventing inactivity-related atrophy.